Fulcrum inks discovery deal with Camp4 Therapeutics
With a new CEO at the helm and its hematological program still under a clinical hold, Fulcrum Therapeutics has signed a licensing and discovery deal with RNA startup Camp4 Therapeutics to develop a treatment for a rare blood disorder.
Diamond-Blackfan anemia is a congenital disease that affects around 5,000 people worldwide, Fulcrum wrote in a press release Monday. Patients who have the disease, usually diagnosed at birth, can be treated with steroids and blood transfusions, according to Boston Children’s Hospital. The only known cure is a stem cell transplant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
